1
|
Mursic D, Badovinac S, Korsic M, Popovic F, Roglic M, Cucevic B, Jakopovic M, Samarzija M. Coexistence of chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer and impact on survival. Lung Cancer 2017. [DOI: 10.1183/1393003.congress-2017.pa4264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
2
|
Jakopovic M, Bitar L, Cucevic B, Plestina S, Mazuranic I, Seiwerth S, Hecimovic A, Vukic Dugac A, Jankovic M, Redzepi G, Samarzija M. First experience with osimertinib in patients with T790M mutation previously treated with EGFR – TKIs in Croatia. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e20518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20518 Background: EGFR T790M mutation is responsible for around 60% cases of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in patients who have lung cancer with an activating EGFR mutation. Methods: We administered osimertinib 80 mg once daily in 8 patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with first and second-line EGFR tyrosine kinase inhibitors. Results: We treated 8 patients with osimertinib with stage IV lung adenocarcinoma. Four patients were males and four were females, median age 62 (raging from 54 to 82). Four patients were never smoker, and four were ex-smokers. All patients had initially deletion 19 in EGFR gene and then developed T790M mutation. In all patients T790M was proven from tumor tissue. Majority of patients were ECOG 1. All patients were previously treated with first or second line EGFR TKIs (erlotinib, gefitinib or afatinib) and had radiologically documented disease progression. Three patients were treated with osimertinib in third line setting, 2 in fourth, one in fifth, one in sixth and one even in tenth line setting. Median time to response was 4 weeks (raging from 3 to 7). All 8 patients had partial response (PR) with still no recorded disease progression. Duration of response is from 7 to 46 weeks and still ongoing. No significant side effects were observed. Conclusions: Osimertinib is highly active in patients with lung adenocarcinoma which harbor EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. There were no serious side effects of treatment.
Collapse
Affiliation(s)
| | - Lela Bitar
- Univeristy Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | | | | | | | | | | | - Gzim Redzepi
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | |
Collapse
|
3
|
Jakopovic M, Brcic L, Misic M, Bubanovic G, Seiwerth F, Drpa G, Cucevic B, Roglic M, Plestina S, Kukulj S, Smojver-Jezek S, Seiwerth S, Samarzija M. P1.02-049 EGFR, KRAS and ALK Gene Alterations in Lung Cancer Patients in Croatia. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Badovinac S, Korsic M, Mursic D, Samarzija M, Cucevic B, Roglic M, Jakopovic M. Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer. J Thorac Dis 2016; 8:1497-503. [PMID: 27499936 DOI: 10.21037/jtd.2016.05.56] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Lung cancer is the leading cause of cancer deaths and the non-small cell lung cancer (NSCLC) represents 80% of all cases. In most cases when diagnosed, it is in locally advanced or metastatic stage, when platinum based doublet chemotherapy is the established therapeutic option for majority of the patients. Predictive factors to filter the patients who will benefit the most from the chemotherapy are not clearly defined. Objective of this study was to explore predictive value of pre-treatment C-reactive protein (CRP), fibrinogen and their interaction, for the response to the frontline chemotherapy. METHODS In this retrospective cohort study 170 patients with locally advanced and metastatic NSCLC were included. Relationship between baseline level of CRP and fibrinogen and response to the frontline chemotherapy was assessed. RESULTS We found that pre-treatment CRP and fibrinogen values were statistically significantly correlated. Chemotherapy and CRP, fibrinogen, and their interaction were independently significantly associated with disease control rate at re-evaluation. There was statistically significant difference in median pre-treatment CRP level between the patients with disease control or progression at re-evaluation, 13.8 vs. 30.0 mg/L respectively, P=0.026. By Johnson-Neyman technique we found that in patients with initial fibrinogen value below 3.5 g/L, CRP level was significantly associated with disease control or progression of the disease. Above this fibrinogen value the association of CRP and disease control was lost. CONCLUSIONS The findings from this study support the growing evidence of inflammation and cancer relationship, where elevated pre-treatment level of CRP has negative predictive significance on the NSCLC frontline chemotherapy response.
Collapse
Affiliation(s)
- Sonja Badovinac
- Department for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Marta Korsic
- Department for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Davorka Mursic
- Department for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Miroslav Samarzija
- Department for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Branka Cucevic
- Department for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Mihovil Roglic
- Department for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Marko Jakopovic
- Department for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
| |
Collapse
|
5
|
Jakopovic M, Bitar L, Markelic I, Seiwerth F, Dzubur F, Hecimovic A, Cucevic B, Mazuranic I, Redzepi G, Vukic Dugac A, Jankovic Makek M, Samarzija M. The effect of emergency presentation on survival of lung cancer patients. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e18041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Lela Bitar
- Univeristy Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - Fedza Dzubur
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | | | - Gzim Redzepi
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | | |
Collapse
|
6
|
Jakopovic M, Brcic L, Misic M, Seiwerth F, Drpa G, Cucevic B, Plestina S, Roglic M, Kukulj S, Smojver-Jezek S, Seiwerth S, Samarzija M. Rates of EGFR, KRAS and ALK gene changes in lung cancer patients in Croatia. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e23238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | - Gordana Drpa
- University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Badovinac S, Korsic M, Cucevic B, Slivnjak V, Dugac AV, Jakopovic M. Stress cardiomyopathy following acute ischemic stroke during flexible bronchoscopy: a rare sequence of complications. J Bras Pneumol 2014; 39:525-8. [PMID: 24068278 PMCID: PMC4075863 DOI: 10.1590/s1806-37132013000400020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Affiliation(s)
- Sonja Badovinac
- University of Zagreb, School of Medicine, University Hospital Centre Zagreb, Department of Respiratory Diseases, Zagreb, Croatia
| | | | | | | | | | | |
Collapse
|
8
|
Budimir B, Kukulj S, Serdarevic M, Samarzija M, Cucevic B. Pulmonary small cell carcinoma with heterotopic ossification—Unique case report and review of literature. Lung Cancer 2012. [DOI: 10.1016/j.lungcan.2012.05.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
9
|
Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012; 13:292-9. [DOI: 10.1016/s1470-2045(11)70339-4] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-40. [PMID: 19767093 DOI: 10.1016/s0140-6736(09)61497-5] [Citation(s) in RCA: 831] [Impact Index Per Article: 55.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Several studies have shown the efficacy, tolerability, and ease of administration of pemetrexed-an antifolate antineoplastic agent-in patients with advanced non-small-cell lung cancer. We assessed pemetrexed as maintenance therapy in patients with this disease. METHODS This randomised double-blind study was undertaken in 83 centres in 20 countries. 663 patients with stage IIIB or IV disease who had not progressed on four cycles of platinum-based chemotherapy were randomly assigned (2:1 ratio) to receive pemetrexed (500 mg/m(2), day 1) plus best supportive care (n=441) or placebo plus best supportive care (n=222) in 21-day cycles until disease progression. Treatment was randomised with the Simon and Pocock minimisation method. Patients and investigators were masked to treatment. All patients received vitamin B(12), folic acid, and dexamethasone. The primary endpoint of progression-free survival and the secondary endpoint of overall survival were analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00102804. FINDINGS All randomly assigned participants were analysed. Pemetrexed significantly improved progression-free survival (4.3 months [95% CI 4.1-4.7] vs 2.6 months [1.7-2.8]; hazard ratio [HR] 0.50, 95% CI 0.42-0.61, p<0.0001) and overall survival (13.4 months [11.9-15.9] vs 10.6 months [8.7-12.0]; HR 0.79, 0.65-0.95, p=0.012) compared with placebo. Treatment discontinuations due to drug-related toxic effects were higher in the pemetrexed group than in the placebo group (21 [5%] vs three [1%]). Drug-related grade three or higher toxic effects were higher with pemetrexed than with placebo (70 [16%] vs nine [4%]; p<0.0001), specifically fatigue (22 [5%] vs one [1%], p=0.001) and neutropenia (13 [3%] vs 0, p=0.006). No pemetrexed-related deaths occurred. Relatively fewer patients in the pemetrexed group than in the placebo group received systemic post-discontinuation therapy (227 [51%] vs 149 [67%]; p=0.0001). INTERPRETATION Maintenance therapy with pemetrexed is well tolerated and offers improved progression-free and overall survival compared with placebo in patients with advanced non-small-cell lung cancer. FUNDING Eli Lilly.
Collapse
|
11
|
Zielinski CC, Yang S, Santoro A, Ramlau R, Liepa AM, Peterson P, Brodowicz T, Madhavan J, Franke FA, Cucevic B. Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 2006; 52:155-63. [PMID: 16569462 DOI: 10.1016/j.lungcan.2006.01.006] [Citation(s) in RCA: 243] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2005] [Revised: 12/28/2005] [Accepted: 01/09/2006] [Indexed: 11/27/2022]
Abstract
PURPOSE The primary objective of this randomized phase III study was to show significant difference in median time to progression (TTP) in patients with advanced NSCLC treated with single-agent gemcitabine maintenance therapy versus best supportive care following gemcitabine plus cisplatin initial first-line therapy. PATIENTS AND METHODS Chemonaive patients with stage IIIB/IV NSCLC received gemcitabine 1,250 mg/m(2) (days 1 and 8) plus cisplatin 80 mg/m(2) (day 1) every 21 days. Patients achieving objective response or disease stabilization following initial gemcitabine plus cisplatin therapy were randomized (2:1 fashion) to receive maintenance gemcitabine (1,250 mg/m(2) on days 1 and 8 every 21 days) plus best supportive care (GEM arm), or best supportive care only (BSC arm). RESULTS Between November 1999 and November 2002, we enrolled 352 patients (median age: 57 years; stage IV disease: 74%; Karnofsky performance status (KPS) >80: 41%). Following initial therapy, 206 patients were randomized and treated with gemcitabine (138) or best supportive care (68). TTP throughout the study period was 6.6 and 5 months for GEM and BSC arms, respectively, while values for the maintenance period were 3.6 and 2.0 months (for p < 0.001 for both). Median overall survival (OS) throughout study was 13.0 months for GEM and 11.0 months for BSC arms (p = 0.195). The toxicity profile was mild, with neutropenia being most common grade 3/4 toxicities. CONCLUSION Maintenance therapy with gemcitabine, following initial therapy with gemcitabine plus cisplatin, was feasible, and produced significantly longer TTP compared to best supportive care alone. Further studies are warranted to establish the place of maintenance chemotherapy in patients with advanced NSCLC.
Collapse
|
13
|
O'Brien M, Ciuleanu T, Tsekov H, Shparyk Y, Cucevic B, Juhasz G, Ross G, Dane G, Crofts T. O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80291-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Krzakowski M, Wenczl M, Brodowicz T, Tzekova V, Ramlau R, Ghilezan N, Cucevic B, Ulsperger E, Zielinski C, Zwitter M. Gemcitabine and cisplatin (GC) +/− subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Krzakowski
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - M. Wenczl
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - T. Brodowicz
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - V. Tzekova
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - R. Ramlau
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - N. Ghilezan
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - B. Cucevic
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - E. Ulsperger
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - C. Zielinski
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| | - M. Zwitter
- M. Sklodowska-Curie Memorial Dept of Lung & Thoracic Tumours, Warsaw, Poland; Markusovszky Hospital, Szombathely, Hungary; University Hospital Vienna, Vienna, Austria; University Hospital “Queen Joanna”, Sofia, Bulgaria; Great Poland Lung Diseases Center, Poznan, Poland; Oncology Institute, Cluj-Napoca, Romania; Hospital for Lung Diseases “Jordanovic”, Zagreb, Croatia; Krankenhaus Lainz, Vienna, Austria; Institute of Oncology, Ljubljana, Slovenia
| |
Collapse
|